← Issue №9/ week of Aug 30, 2026/Pancreas/Biliary

Proteomic landscape of pan-tissue neuroendocrine carcinomas defines subtype-specific functional architectures, biomarkers and therapeutic targets.

From GI Signals issue №9: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary prospective cohort · n=267 · Aug 26, 2026 · Gut · IF 24.6

Proteomic landscape of pan-tissue neuroendocrine carcinomas defines subtype-specific functional architectures, biomarkers and therapeutic targets.

Basic sciencebasic sciencetranslationalbiomarker
Clinical takeawayNo clinical action yet: a preclinical finding in NEC models, identifying a potential therapeutic target.
What it foundNAD+ dependency identified as a metabolic vulnerability in gastroenteropancreatic NEC subtype H, with NAMPT inhibition achieving complete tumor regression in vivo.
ContextOpens a new avenue for targeted therapy in a subset of NECs, challenging the current one-size-fits-all approach.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Ge F … He J · Gut · IF 24.6 · PubMed ↗Permalink
← Read the whole of issue №9 Every paper GI Signals surfaces gets a page like this one. All issues